Jump to navigation

  • Contact us
  • Data catalog (GHDx)
  • Research library
Home
Main menu
  • Home
  • Research and analysis
    • Global Burden of Disease (GBD)
    • Health policy and planning
    • Health by location
    • Health risks and issues
      • Air pollution
      • Alcohol
      • Antimicrobial resistance
        • AMR home
        • News and events
        • Publications
        • Infographics
        • Our approach
      • Burden of Proof
      • Child health
      • Diet
      • Maternal health
      • Smoking and tobacco
    • Diseases and injuries
    • Training on our research
    • Research and news library
  • Data tools and practices
    • Interactive data visuals
    • Data sources
    • How we collect data
    • Data practices
    • Verbal autopsy tool
    • Training on tools
    • Data for the private sector
  • News and events
    • News media
    • Blogs
    • Events
    • Media contacts
  • About us
    • Vision and mission
    • Diversity, Equity, and Inclusion
    • Our people
    • Awards
    • Careers
    • History
    • Governance
    • Contact us

Explore section

Antimicrobial resistance

  • AMR home
  • News and events
  • Publications
  • Infographics
  • Our approach

Antimicrobial resistance (AMR)


Twitter
Facebook
Google+
LinkedIn
Pinterest
Email
Print

scientist examines a petri dish

AMR poses a major threat to human health around the world

AMR occurs when microorganisms, such as bacteria, adapt in ways that make currently available treatments for infections less effective. Action is needed to reduce the impact of AMR worldwide.

Key findings from IHME

Based on estimates for 204 countries and territories, IHME’s paper, “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis”, reveals that AMR has become a leading cause of death globally.

At least 1.27 million deaths were linked to AMR in 2019.
An estimated 4.95 million people who died in 2019 suffered from drug-resistant bacterial infections. The largest burden occurred in the sub-Saharan Africa region.

 

1 in 5 people who died was a child under 5 years old.
Many of these deadly infections in children would have been treatable with current medicines if the bacteria had not become resistant.

 

Only 7 pathogens caused more than 80,000 deaths each in 2019.
These were S. aureus, E. coli, K. pneumoniae, S. pneumoniae, A. baumannii, M. tuberculosis, and P. aeruginosa.

 

 

Explore the data

Explore the MICROBE data visual.

Use the MICROBE (Measuring Infectious Causes and Resistance Outcomes for Burden Estimation) tool to visualize the health outcomes of infections, pathogens, and antimicrobial resistance across different countries and regions. 

Interact with the data visual

 

How do we combat AMR?

Bacteria are gaining resistance faster than new antibiotics can be developed, but decision-makers can use this information about AMR to inform development of new drugs or vaccines. Effective vaccines are particularly important since they would reduce the need for antibiotic use.

In the meantime, essential medicines need to be made accessible. In addition, more data is needed, particularly from lower-income countries; increasing high-quality tracking of AMR would bring greater clarity to this issue.

There are more immediate actions that can help countries around the world protect their health systems against the threat of AMR:

  • Take greater action to monitor and control infections, globally, nationally and within individual hospitals.
  • Accelerate our support for infection prevention and control, as well as expand access to vaccines and clean water and sanitation.
  • Optimize our use of antibiotics unrelated to treating human disease, such as in food and animal production – taking a One Health approach and recognizing the interconnection between human and animal health.
  • Be thoughtful about our use of antimicrobial treatments – expanding access to lifesaving antibiotics where needed, minimizing use where it is not necessary to improve human health, and acting according to the World Health Organization Global Action Plan and AWaRE guidelines.
  • Increase funding at every stage of the development pipeline for new antimicrobials targeting priority pathogens – from research for high priority bacteria, such as K. pneumoniae and E. coli, to securing access through innovative market solutions.
Read the research
 

IHME Director, Dr. Christopher Murray, reviews key findings from our AMR research and what these findings mean for health policy decision-makers.

 

Common questions about AMR

What is antimicrobial resistance (AMR)?

Antimicrobial resistance occurs when changes in bacteria or other pathogens cause the drugs used to treat infections to become less effective.

What causes AMR?

When antibiotics are misused or overused, resistance can develop. Lack of access to clean water, handwashing facilities, and general sanitation and hygiene increases the spread of pathogens, as does inadequate control and prevention of diseases in health care settings. In places where diagnostic capabilities (such as microbiology laboratories) are limited, it can be difficult to pinpoint the cause of an infection and which drugs will work best to combat it. 

Why is AMR a threat?

When first developed, antibiotics were a major breakthrough in medical science, providing reliable treatments for infectious diseases. But as organisms become resistant to drugs, we have fewer tools in our treatment toolbox. Some bacteria are already resistant to multiple drugs, and there are concerns about pathogens developing resistance to all current therapies. Such a “superbug” could spread unchecked through populations, potentially causing another global pandemic. 

Which diseases are resistant to antibiotics?

Various types of infections are caused by resistant bacteria, including infections of the lower respiratory tract, urinary tract, bloodstream, and abdomen. 

Who is at risk?

Children under 5 years are at particular risk of acquiring an AMR infection because they interact with more unsanitary environments and have a less developed immune system. Elderly people, especially those with comorbidities, are similarly threatened. As AMR increases, more and more people will be at risk. 

Related Content

Publications

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Antimicrobial resistance (AMR) poses a major threat to human health around the world. Previous publications have estimated the effect of AMR on incidence, deaths, hospital length of stay, and healt...
The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis

This study presents the most comprehensive set of regional and country-level estimates of AMR burden in the WHO European region to date

Datasets

Global Bacterial Antimicrobial Resistance Burden Estimates 2019

Antimicrobial resistance

  • AMR home
  • News and events
  • Publications
  • Infographics
  • Our approach

Sign up for IHME News

Stay connected

    

Sign up for our newsletter

  • Contact us
  • Donate
  • Privacy policy

© 2023

         Home to Highly Cited Researchers 2022, Clarivate

  • Home
  • Research and analysis
    • Global Burden of Disease (GBD)
    • Health policy and planning
    • Health by location
    • Health risks and issues
    • Diseases and injuries
    • Training on our research
    • Research and news library
  • Data tools and practices
    • Interactive data visuals
    • Data sources
    • How we collect data
    • Data practices
    • Verbal autopsy tool
    • Training on tools
    • Data for the private sector
  • News and events
    • News media
    • Blogs
    • Events
    • Media contacts
  • About us
    • Vision and mission
    • Diversity, Equity, and Inclusion
    • Our people
    • Awards
    • Careers
    • History
    • Governance
    • Contact us